FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), in combination with the biologic therapy Bevacizumab (Avastin), for the first-line treatment of patients with liver metastases from colorectal carcinoma in whom surgical resection is not feasible.

本先导性研究将评估由FOLFOX6化疗方案联合SIR-Spheres钇-90微球（SIR-Spheres yttrium-90 microspheres，此类放化疗方案亦被称为"chemo-SIRT"），联合生物治疗药物贝伐珠单抗（Bevacizumab，商品名安维汀（Avastin））的安全性与有效性，该方案用于无法接受手术切除的结直肠癌肝转移患者的一线治疗。